Could The Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) Ownership Structure Tell Us Something Useful?
Could The Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) Ownership Structure Tell Us Something Useful?
Every investor in Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd (SZSE:002864) should be aware of the most powerful shareholder groups. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. Warren Buffett said that he likes "a business with enduring competitive advantages that is run by able and owner-oriented people." So it's nice to see some insider ownership, because it may suggest that management is owner-oriented.
陝西盤龍藥業股份有限公司(深交所股票代碼：002864)的每一位投資者都應該知道最強大的股東羣體。一般來説，隨着公司的成長，機構會增加他們的持股。相反，隨着時間的推移，內部人士往往會減少他們的持股。沃倫·巴菲特説，他喜歡“一家由有能力、以所有者為導向的人經營的、具有持久競爭優勢的企業”。因此，看到一些內部人持股是件好事，因為這可能表明管理層是以所有者為導向的。
Shaanxi Panlong Pharmaceutical Group Limited By Share is not a large company by global standards. It has a market capitalization of CN¥3.9b, which means it wouldn't have the attention of many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions are not really that prevalent on the share registry. We can zoom in on the different ownership groups, to learn more about Shaanxi Panlong Pharmaceutical Group Limited By Share.
以全球標準來看，陝西盤龍藥業集團股份有限公司並不是一家大公司。它的市值為人民幣39億元，這意味着它不會受到許多機構投資者的關注。看看我們關於所有權組的數據(如下)，似乎機構在股票登記處並不是真的那麼普遍。我們可以放大不同的所有制集團，通過分享瞭解更多關於陝西盤龍藥業集團有限公司的信息。
View our latest analysis for Shaanxi Panlong Pharmaceutical Group Limited By Share
查看我們對陝西盤龍藥業集團股份有限公司的最新分析
What Does The Lack Of Institutional Ownership Tell Us About Shaanxi Panlong Pharmaceutical Group Limited By Share?
關於陝西盤龍藥業股份有限公司，機構所有權的缺失告訴了我們什麼？
Small companies that are not very actively traded often lack institutional investors, but it's less common to see large companies without them.
交易不太活躍的小公司往往缺乏機構投資者，但大公司沒有機構投資者的情況較少。
There are many reasons why a company might not have any institutions on the share registry. It may be hard for institutions to buy large amounts of shares, if liquidity (the amount of shares traded each day) is low. If the company has not needed to raise capital, institutions might lack the opportunity to build a position. Alternatively, there might be something about the company that has kept institutional investors away. Institutional investors may not find the historic growth of the business impressive, or there might be other factors at play. You can see the past revenue performance of Shaanxi Panlong Pharmaceutical Group Limited By Share, for yourself, below.
一家公司可能沒有在股票登記處登記任何機構的原因有很多。如果流動性(每天交易的股票數量)很低，機構可能很難購買大量股票。如果該公司不需要籌集資金，機構可能缺乏建立頭寸的機會。或者，該公司可能有某些方面讓機構投資者望而卻步。機構投資者可能不會覺得這項業務的歷史性增長令人印象深刻，或者可能有其他因素在起作用。您可以查看陝西盤龍藥業集團有限公司過去的收入業績，按份額計算，如下所示。
Shaanxi Panlong Pharmaceutical Group Limited By Share is not owned by hedge funds. The company's largest shareholder is Xiaolin Xie, with ownership of 43%. The second and third largest shareholders are Shuiping Zhang and Zhihong Zhang, with an equal amount of shares to their name at 1.3%. Zhihong Zhang, who is the third-largest shareholder, also happens to hold the title of Member of the Board of Directors.
陝西盤龍醫藥集團股份有限公司不為對衝基金所有。該公司最大股東為謝曉林，持股43%。第二和第三大股東是張水平和張志鴻，持股比例相同，持股比例為1.3%。作為第三大股東的張志宏也恰好持有董事會成員的頭銜。
A deeper look at our ownership data shows that the top 15 shareholders collectively hold less than half of the register, suggesting a large group of small holders where no single shareholder has a majority.
更深入地研究我們的所有權數據就會發現，前15名股東總共持有的股份不到登記冊的一半，這表明有一大羣小股東，沒有單一股東佔多數。
Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Our information suggests that there isn't any analyst coverage of the stock, so it is probably little known.
研究機構持股是衡量和篩選股票預期表現的好方法。通過研究分析師的情緒，也可以達到同樣的效果。我們的信息顯示，分析師沒有對該股進行任何報道，因此它可能鮮為人知。
Insider Ownership Of Shaanxi Panlong Pharmaceutical Group Limited By Share
陝西盤龍藥業集團股份有限公司內部人持股
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
儘管對內部人的準確定義可能是主觀的，但幾乎每個人都認為董事會成員是內部人。管理層最終要向董事會負責。然而，經理人擔任執行董事會成員並不少見，尤其是如果他們是創始人或首席執行官的話。
I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.
我通常認為內部人持股是一件好事。然而，在某些情況下，這會讓其他股東更難讓董事會對決策負責。
It seems insiders own a significant proportion of Shaanxi Panlong Pharmaceutical Group Limited By Share Ltd. Insiders have a CN¥1.9b stake in this CN¥3.9b business. It is great to see insiders so invested in the business. It might be worth checking if those insiders have been buying recently.
內部人士似乎持有陝西盤龍藥業股份有限公司相當大的比例。內部人士在這筆39億元人民幣的業務中持有19億元人民幣的股份。看到內部人士如此投資於這項業務，真是太好了。或許值得一查的是，這些內部人士最近是否一直在買入。
General Public Ownership
一般公有制
The general public, who are usually individual investors, hold a substantial 50% stake in Shaanxi Panlong Pharmaceutical Group Limited By Share, suggesting it is a fairly popular stock. This level of ownership gives investors from the wider public some power to sway key policy decisions such as board composition, executive compensation, and the dividend payout ratio.
普通公眾通常是個人投資者，他們持有陝西盤龍醫藥集團有限公司50%的股份，這表明這是一隻相當受歡迎的股票。這種所有權水平使更廣泛的公眾投資者有一定的權力影響關鍵政策決策，如董事會組成、高管薪酬和股息支付率。
Next Steps:
接下來的步驟：
While it is well worth considering the different groups that own a company, there are other factors that are even more important. Consider risks, for instance. Every company has them, and we've spotted 1 warning sign for Shaanxi Panlong Pharmaceutical Group Limited By Share you should know about.
雖然考慮擁有一家公司的不同集團是很值得的，但還有其他更重要的因素。例如，考慮一下風險。每家公司都有，我們發現了陝西盤龍藥業股份有限公司的一個警示標誌，你應該知道。
Of course, you might find a fantastic investment by looking elsewhere. So take a peek at this free list of interesting companies.
當然了,如果你把目光投向別處，你可能會發現這是一筆很棒的投資。所以讓我們來看看這個免費有趣的公司名單。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注：本文中的數字是使用過去12個月的數據計算的，指的是截至財務報表日期的最後一個月的12個月期間。這可能與全年的年度報告數字不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有什麼反饋嗎？擔心內容嗎？保持聯繫直接與我們聯繫。或者，也可以給編輯組發電子郵件，地址是implywallst.com。
本文由Simply Wall St.撰寫，具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論，我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議，也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意，我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
譯文內容由第三人軟體翻譯。